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White matter (WM) injury in relation to acute neurologic conditions, especially stroke, has 
remained obscure until recently. Current advances in imaging technologies in the field of 
stroke have confirmed that WM injury plays an important role in the prognosis of stroke 
and suggest that WM protection is essential for functional recovery and post-stroke 
rehabilitation. However, due to the lack of a reproducible animal model of WM injury, the 
pathophysiology and mechanisms of this injury are not well studied. Moreover, produc-
ing selective WM injury in animals, especially in rodents, has proven to be challenging. 
Problems associated with inducing selective WM ischemic injury in the rodent derive 
from differences in the architecture of the brain, most particularly, the ratio of WM to gray 
matter in rodents compared to humans, the agents used to induce the injury, and the 
location of the injury. Aging, gender differences, and comorbidities further add to this 
complexity. This review provides a brief account of the techniques commonly used to 
induce general WM injury in animal models (stroke and non-stroke related) and highlights 
relevance, optimization issues, and translational potentials associated with this particular 
form of injury.
Keywords: corpus callosum, lysophosphatidylcholine, mouse, NOS inhibitor, posterior limb internal capsule, 
stroke, vasoconstriction
introduction
The human brain comprises both gray matter and white matter (WM), with the latter constitut-
ing roughly 60% of the total volume. Gray matter consists of neuronal cell bodies, their dendrites 
and axons, glial cells, and blood vessels (1). On the other hand, WM consists of myelinated and 
unmyelinated axons that connect various gray matter areas of the brain and support communication 
between neurons, as well as convey information among the network of efferent and afferent axonal 
Abbreviations: CBF, cerebral blood flow; CC, corpus callosum; EB, ethidium bromide; ET-1, endothelin 1; eNOS, endothelial 
NOS; L-NIO, L-N5-(1-iminoethyl)ornithine; LPC, lysophosphatidylcholine; LPS, lipopolysaccharide; PLIC, posterior limb 
internal capsule; WM, white matter.
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fibers. Disruption of these conduction pathways may cause 
motor and sensory dysfunction, neurobehavioral syndromes, and 
cognitive impairment (2–4). In clinical settings, WM injury can 
occur at any time in the life span, such as with the development 
of periventricular leukomalacia due to hypoxic ischemic injury in 
infants, cardiac arrest and stroke in adults, and vascular dementia 
in the elderly (5–8). WM injury is the major cause of paresis in 
all types of stroke (9). Most obviously this is true for lacunar 
infarcts, which comprise about 25% of all strokes, and for lower 
extremity paresis in large vessel distribution strokes (except in 
the rare circumstance that the anterior cerebral artery territory 
is involved). However, because anterior circulation large vessel 
strokes are almost always due to clots embolizing or propagating 
to the carotid T-junction or the proximal middle cerebral artery, 
and because infarcts in both locations cause ischemia in the 
posterior periventricular WM, through which corticospinal and 
corticobulbar pathways pass, ischemic WM injury also accounts 
for most upper extremity paresis in large vessel distribution 
strokes. Furthermore, the site of periventricular WM lesions that 
cause paresis is also the site of crossing callosal fibers. Damage to 
these may contribute to apraxia after left brain stroke and may 
interfere with language recovery after stroke.
Thus, the extent to which WM injuries contribute to neurologi-
cal impairment after stroke and the frequency with which WM 
damage contributes to other neurologic disorders highlights the 
need for therapeutic intervention strategies aimed at ameliorating 
WM damage or promoting WM recovery, as well as the need to 
dissect the molecular mechanisms involved in the pathophysiol-
ogy of this injury. This review focuses essentially on techniques 
reported to induce WM injury. For other topics such as WM 
injury induced by traumatic brain injury, the pathophysiology of 
WM injury, WM hypersensitivity, and genetics variants leading 
to stroke and WM injury, which are beyond the scope of this 
paper, see reviews (10–17) and original research articles (18–20).
Broad Classifications of Animal Models 
with wM injuries
Attempts have recently been made to develop animal models 
with WM injury; however, all of these WM injury models have 
certain limitations. A majority of experimental studies have been 
designed using rodents, despite their having only about 14% 
of the relative WM volume of humans (1). Although disease 
models using primates or other higher order mammals are 
more readily translated to the human brain, small rodents are 
privileged for preclinical testing because they are cost effective 
and easy to acquire, handle, and monitor from a physiological 
standpoint. Furthermore, murine models provide researchers 
more flexibility in characterizing disease mechanisms because of 
the availability of genetically modified (transgenic or knockout) 
animals. The variety of methods used to induce WM injury in 
rodents reflects not only the complexity of the disease, but also 
the need for different paradigms to identify mechanisms that 
cause WM damage. Such considerations provide the foundation 
for the development of preclinical novel therapeutic approaches. 
In general, WM lesion models can be classified into two main 
categories, as discussed below.
Focal wM injury
Focal WM injuries are produced at a specific locus in a WM 
region of the brain. Periventricular WM (PVWM) and posterior 
limb internal capsule (PLIC) are the most commonly targeted 
areas to produce injury in WM injury models (Figure 1). PVWM 
injuries are produced by targeting the corpus callosum (CC). The 
PLIC, which contains corticospinal tracts from the motor cortex, 
can be targeted to induce motor deficits that are important in 
determining the efficacy of a therapeutic approach when dealing 
with functional outcomes (see Table 1).
Global wM injury
Global WM injuries are reflected by diffuse axonal injury 
occurring in the entire brain as a result of hypoxic/ischemic 
brain injury, heightened inflammatory states resulting from 
autoimmune diseases or infection, and/or exposure to demy-
elinating agents. It is well recognized that the perinatal WM is 
susceptible to hypoxic/ischemic injury, especially in the preterm 
period (47). A well-established model of perinatal hypoxic/
ischemic injury is unilateral ligation of one common carotid 
artery (CCA) in combination with hypoxia in the neonatal 
rodent. It will result in a decrease in cerebral blood flow (CBF) 
in the middle cerebral artery territory, which corresponds to 
clinical birth asphyxia (48). Diffused WM injury may also occur 
in global hypoperfusion, which commonly occurs in cardiac 
arrest patients. In this context, Shibata and colleagues devel-
oped an adult rodent model of chronic cerebral hypoperfusion 
that provided further insight into mechanisms of WM injury 
pathogenesis (35).
ischemic Stroke-Related Focal wM  
injury Models
Determining the damage to specific regions of motor pathways 
can help predict potential functional outcomes. An animal model 
of a focal WM infarct has been developed using stereotaxic injec-
tions of selective drugs in rodents. Stereotactic delivery of selec-
tive vasoconstrictors or demyelinating agents induces the local 
degeneration of WM in a distinct region of the brain by ischemia 
or the loss of myelin. Subcortical WM, such as the PVWM and 
the PLIC, contains descending axonal fibers originating in the 
motor cortex and ascending fibers conveying sensory informa-
tion to the somatosensory cortex. Therefore, the loss of these 
connections, as observed in stroke in general and in WM injury 
in particular, results in a significant clinical phenotype reflected 
by substantial sensorimotor deficits. Considering the importance 
of these networks and connections, it is important to develop a 
WM injury model by targeting PVWM or PLIC.
Target Brain Regions to induced  
Focal wM injury
Paraventricular White Matter
PVWM refers to the WM adjacent to the bodies of the lateral 
ventricles. It includes ascending and descending fibers in 
continuation with the internal capsule (the corona radiata), 
callosal fibers, and, more laterally, long anterior–posterior 
fasciculi.
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Periventricular leukomalacia in infants is caused by a 
decrease of blood or oxygen flow during the perinatal period 
and is characterized by necrosis, astrogliosis, microglial infiltra-
tion, and depletion of premyelinating oligodendrocytes in the 
PVWM (49, 50). Periventricular leukomalacia most often occurs 
in premature infants. It is associated with neurodevelopmental 
impairments such as cerebral palsy, with or without mental 
retardation, learning disability, or epilepsy (48, 51). White 
matter injuries in PVWM are associated with cognitive and 
emotional decline (52, 53). Executive, and to a lesser extent, 
episodic memory formation and declarative memory retrieval 
are particularly susceptible to deep WM injury because of the 
particular dependency of these functions on the integrity of long 
WM pathways (54).
In an effort to develop relevant animal models, several stud-
ies have successfully induced infarction and/or demyelination 
by targeting the PVWM (21, 29–31). Unfortunately, in contrast 
to what has been reported in the human studies, these animal 
lesion models have not been associated with significant func-
tional deficits (Table 1), and further refinement is warranted.
Posterior Limb Internal Capsule
In humans, the PLIC contains corticospinal fibers and sensory 
projections from the thalamus deriving from both lemniscal and 
anterolateral systems. The anterior limb of the internal capsule 
includes frontopontine and thalamocortical projections, which 
modulate higher cognitive functioning (55). The PLIC is vascu-
larized by the anterior choroidal branches of the internal carotid 
artery and lenticulostriate branches of the middle cerebral 
artery. Damage to corticospinal motor fibers in the PLIC results 
in sensorimotor deficits in patients. In human stroke, damage to 
sensorimotor fibers passing through the PLIC is by far the most 
important contributor to hemiplegia or hemiparesis, although 
this damage most often occurs more rostrally, in the PVWM 
or the centrum semiovale (9). Paresis is characteristically worst 
in the arm but often involves the face and lower extremity. 
Dysarthria, dysphagia, and sensory symptoms may also be 
present in these patients (8). With stereotaxic injection of the 
vasoconstricting agent endothelin 1 (ET-1) in the PLIC, Frost 
et al. (24) and Lecrux et al. (25) induced infarction in the PLIC 
that was associated with functional deficits (24, 25). Thus, selec-
tive targeting of the PLIC by vasoconstricting or demyelinating 
agents can be used to induce a reproducible WM injury model 
with anatomical and functional deficits.
FiGURe 1 | Representative illustrations of targets to induce focal white matter injury in rodents. In rodents, only a small percentage of the brain is WM and 
WM is mostly located in the periventricular white matter, posterior limb internal capsule, and striatum. Therefore, all of the rodent models of WM injury employ one or 
more of these areas.
vasoconstricting Agents Used to induce  
Focal wM injury
Vasoconstrictors have been reported to selectively induce focal 
WM injuries. Potent vasoconstrictors are potential tools that 
need to be fully exploited to further evaluate the mechanisms 
associated with ischemic WM injury and potential therapeutic 
treatments. The following is a list of some of the vasoconstrictors 
that are commonly being used to develop WM injuries in animals.
Endothelin 1
Endothelin 1, a 21-amino acid peptide that is produced by 
vascular endothelial cells, is a potent vasoconstrictor (56–58). 
It participates in the development of atherosclerosis, hyperten-
sion, and vasospasm following subarachnoid hemorrhage (59). 
ET-1 coexists with other isoforms, ET-2 and ET-3, which are 
synthesized by a variety of cells, including glial cells and neurons 
(60–63). Within the central nervous system, ET-1 is distributed 
widely within the brain and spinal cord (60, 64–66), but it cannot 
cross the blood–brain barrier (67, 68). Two classes of ET receptors, 
ETA and ETB, exist in many tissues. The ETA receptor has a high 
affinity for ET-1 and ET-2, but a low affinity for ET-3, whereas the 
ETB receptor has equal affinity for all three isoforms (69).
At present, the cellular mechanism of ET secretion in neurons 
and glial cells is poorly understood because the content of ET in 
neurons and glia is far less than what is found in endothelial cells. 
ET is thought to bind to its receptors and mobilize intracellular 
calcium via phospholipase C activation and/or through calcium 
channels (70). Application of ET-1 in the subcortical WM (such 
as the PVWM or PLIC) will reduce blood flow, disrupt myelin, 
and cause axonal injury (12, 71). When ET-1 is administered 
via intraparenchymal injection or applied topically to cerebral 
blood vessels, it elicits a sustained vasoconstriction and leads to 
a monophasic reduction in microvascular blood flow (72–75). 
Furthermore, the hypoxia of endothelial cells surrounding cerebral 
vasculature after infarction will trigger de novo synthesis of ET-1 
and contribute further to vasospasm-induced brain ischemia (76). 
The application of ET-1 has been shown to effectively induce stroke 
in rats (75, 77, 78). However, additional precaution should be taken 
while considering this model because application of ET-1 topically 
or in brain parenchyma can lead to non-specific jury to the WM and 
gray matter. Indeed, when ET-1 or other vasoconstriction agents 
are applied in brain parenchyma, such as striatum, it affects the 
cerebral fibers network; however, other striatal circuitries are also 
affected non-selectively. A  striatal-induced stroke/lesion is likely 
TABLe 1 | Preclinical models of white matter brain injury.
Focal white matter injury Animal Lesion location Morphological changes Functional deficits, reference
eNDOTHeLiN 1 (eT-1)
Mouse CC/PVWM Gliosis, axonal degeneration, myelin loss No report (21)
Mouse Subcortical WM, striatum None No report (22)
Rat CC, striatum Gliosis, demyelination No report (23)
Rat PLIC Demyelination Yes (24)
Rat PLIC Lesion Yes (25)
Rat PLIC Axonal degeneration, myelin loss Yes (26)
AchA OCCLUSiON
Rat IC, lateral and medial 
hypothalamus
Infarct Yes (27)
Pig IC Infarct Yes (28)
PHOSPHATiDYLCHOLiNe
LPC Rat CC/PVWM Demyelination No report (29, 30)
Mouse CC/PVWM Demyelination No report (31)
NOS iNHiBiTOR
L-NAME + ET1 Mouse Subcortical WM, striatum Infarct Yes (22)
L-NIO Mouse Subcortical WM, CC Infarct, demyelination No report (32)
OTHeR
Myelin debris Rat CC/PVWM Gliosis, demyelination No report (33)
Global white matter injury Animal Lesion location Morphological changes Functional deficits, reference
CHRONiC HYPOPeRFUSiON
Bilateral CCA ligation Rat CC, IC, caudate-putamen Hippocampal cell death Cognitive impairment (34)
Mouse Optic tract, CC, IC Demyelination, gliosis No report (35)
Mouse Hippocampus Neuronal death Memory loss (36)
Gerbil Hippocampus, Cortex Gliosis, neuronal death Yes (37)
Gerbil Whole brain Ventricular dilation, atrophy, gliosis, 
demyelination, NF degeneration
No report (38, 39)
Asymmetric CCA ligation Mouse Subcortical WM WM rarefaction, gliosis, axonal damage Motor and cognitive deficits (40)
HYPOXiC-iSCHeMiC iNJURY
Unilateral ligation + hypoxia Rat Cortex, striatum Cell death, atrophy Yes (41)
Rat Hippocampus Demyelination Memory loss (42)
Mouse CC, hippocampus, Thalamus Demyelination, necrosis No report (43)
Hypoxia only Rat CC, PVWM NOS, gliosis, axonal degeneration No report (7)
LPS
Rat CC Demyelination (delayed) Acute motor deficits (44)
Sheep PVWM, cortex Inflammation, gliosis Cardiovascular changes (45)
Sheep IC, EC Demyelination (delayed) No report (46)
AchA, anterior choroidal arteries; CCA, common carotid artery; CC, corpus callosum; EC, external capsule; IC, internal capsule; L-NAME, L-NG-nitroarginine methyl ester; L-NIO, 
L-N5-(1-iminoethyl)ornithine; LPC, lysophosphatidylcholine; NF, neurofilament; NOS, nitric oxide synthase; PLIC, posterior limb internal capsule; PVWM, paraventricular white matter; 
WM, white matter.
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a combination of a white and gray matter lesion. The bundles of 
penetrating corticopetal fibers in the rodent striatum are indeed 
injured or destroyed in such a model. Therefore, in an effort to 
develop a focal WM infarction model that can mimic the lasting 
neurologic deficits, which is a clinical feature of WM stroke, a recent 
report in rodents shows that ET-1 injection into the internal capsule 
results in focal infarction and severe axonal and myelin loss. Such a 
rodent model also exhibit significant functional deficit at 1 month 
post-injection (26). However, when ET-1 is applied to cortical tissue 
in mouse brain, it has produced inconsistent results (22, 79), sug-
gesting dissimilarities between mice and rats in response to ET-1 
because of differences in expression of ET-1 receptor isoforms (80). 
On the other hand, a combination of ET-1 and L-NG-nitroarginine 
methyl ester [L-NAME, a nitric oxide synthase (NOS) inhibitor] 
increased the probability of producing an infarct in mice; however, 
the lesion was still relatively small and strain dependent (22).
Nitric Oxide Synthase Inhibitors
Nitric oxide synthase plays important roles in physiological and 
pathological events, including blood pressure homeostasis, neuro-
transmission, and immune function in the central nervous system 
(81). Endothelial NOS (eNOS) is found in the endothelium of 
cerebral vessels and also in a subset of neurons. Nitric oxide (NO) 
generated by eNOS is crucial for vascular function and hemostasis. 
By contrast, NO produced by the neuronal and inducible isoforms 
of NOS can be neurotoxic (82, 83). Furthermore, overproduction 
of NO may also have pathological consequences (84). Nevertheless, 
NO plays a critical role in neuroprotection against ischemic stroke 
through various processes, including ischemic pre- and post-
conditioning (85–87). Consequently, some of these NOS inhibitors 
are being used to produce focal ischemic brain damage.
L-NAME is an arginine analog commonly used as a potent 
inhibitor of NOS. It has been shown to induce a rapid rise in blood 
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pressure and a decrease in cardiac output (88, 89). It has been 
reported that a striatal injection of 100 mM L-NAME alone in the 
rat produces minor injury, whereas when it is co-administered with 
quinolinic acid (an NMDA receptor agonist), it augments striatal 
injury (90). Similarly, co-administration of L-NAME with ET-1 
augments infarct volume. However, it has also been reported that 
the final outcomes following such combinational treatments are 
strain dependent and produce a relatively small lesion size (22). By 
contrast, L-NAME has also been shown to have neuroprotective 
effects in rodent models of cerebral ischemia. It has reduced the 
effect of ischemic brain injury and prevented blood–brain barrier 
disruption in animal models (91–93).
L-N5-(1-iminoethyl)ornithine (L-NIO, a selective eNOS 
inhibitor) is approximately five times more potent as an eNOS 
inhibitor than any other arginine analog, including L-NAME 
(94). The inhibitory effects of L-NIO are rapid in onset and irre-
versible, in contrast to other arginine analogs (95). Carmichael 
and colleagues demonstrated that microinjection of L-NIO in 
either the cortex or CC induced focal cortical or callosal WM 
stroke (32). This microinjection resulted in axonal fiber loss and 
myelin damage within the CC.
Non-ischemic Stroke-Related Focal wM 
injury Models
ethidium Bromide
Ethidium bromide (EB) has been used extensively to induce demy-
elination in animal models because of its cytotoxic effect on cells. 
Many reports have shown the effectiveness of EB-induced focal 
demyelination in various WM regions of the brain (96–99). The 
size of the injury is dependent on the volume and concentration 
of EB, and survival time points (100). Compared to other demy-
elinating agents, EB administration results in relatively delayed 
remyelination. Oligodendrocyte and astrocyte loss occurs within 
the epicenter of the lesion. Neurons and endothelial cells are less 
sensitive than glia, and axons remain unaffected (101–103).
Myelin-enriched Brain Debris
This method was recently introduced by Clarner and colleagues 
(33). Myelin-enriched debris taken from the CC of 7-week-old 
C57BL/6 mice is homogenized with Precellys© zirconium oxide 
beads. After extraction of the protein contained within the debris 
using the Bradford method, 6500  μg/mL of protein in a total 
volume of 1 μL was stereotactically injected into the CC or the 
cortex of deeply anesthetized animals (33). This direct application 
of myelin-enriched brain debris induces profound myelin loss 
and inflammation.
Demyelinating Agents Used to induce 
Focal wM injury
Lysophosphatidylcholine
The partial hydrolysis of phosphatidylcholines generates 
lysophosphatidylcholine (LPC), which is also known as lysoleci-
thin. This hydrolysis is generally the result of phospholipase A2 
enzymatic action on phospholipids, which generates free fatty 
acids such as arachidonic acids and lysophospholipids such as 
LPC (104). LPC is believed to play an important role in athero-
sclerosis and inflammatory diseases by altering various functions 
in a number of cell types, including monocytes, macrophages, 
and T-cells (105). LPC is a potent demyelinating agent and has 
been used widely to study various aspects of demyelination and 
remyelination in the mature rodent central nervous system (106, 
107) as well as in vitro organotypic cerebellar slice culture (108). 
LPC induces demyelination of the brain by the action of recruited 
macrophages and microglia, which phagocytose nearby myelin. 
Several reports have demonstrated that microinjection of LPC in 
the PVWM and WM regions of the spinal cord results in demyeli-
nation, an increase in proinflammatory genes, and the induction 
of gliosis (29–31, 109–111).
A significant limitation of LPC-induced injury, at least from 
a stroke and rehabilitation point of view, is the potential for 
reversibility of the injury. Lesions rapidly become repopulated 
with oligodendrocyte precursors, which initiate remyelination. In 
rodents, remyelination begins 7 to 14 days post-lesion, depending 
on the location of the lesion and the age of the animal. Most of the 
remyelination is essentially complete by 3–4 weeks (112).
ischemic Stroke-Related Global wM injury
Chronic Cerebral Hypoperfusion Model
Neonatal WM damage in the periventricular region is often 
identified as periventricular leukomalacia. Factors predispos-
ing patients to periventricular leukomalacia include immature 
cerebrovascular development and reduction of CBF in asso-
ciation with hypoxic/ischemic insults such as birth trauma, 
asphyxia, respiratory failure, cardiopulmonary defects, and 
premature birth and/or low birth weight (49). The pathological 
processes involved in global WM injury are still unknown. 
However, the intrinsic vulnerability of oligodendrocyte precur-
sors to hypoxic/ischemic injury is considered to be central to 
the pathogenesis of periventricular leukomalacia. These cells 
are susceptible to a variety of injurious stimuli, including free 
radical exposure, the lack of trophic factors, and excitotoxicity 
resulting from cerebral hypoperfusion, as well as secondary 
events consequent to microglial activation and astrogliosis 
(49). The increased expression of proinflammatory cytokines 
(such as TNFα, IL-1β, and IL-6) in amniotic fluid has also been 
reported as an identifiable risk factor for the development of 
brain WM injury (113).
Since the development of the first rodent neonatal hypoxic/
ischemic brain injury model, this model has been routinely used 
to better understand the neuropathology of stroke in neonates 
(51, 114, 115). The injury in neonatal rat pups at postnatal day 7 
(P7) is induced through unilateral ligation of the CCA followed 
by creation of hypoxia (6–8% oxygen mixed with nitrogen) 
for a certain period of time (51, 114, 115). Brain damage, seen 
histologically, is generally confined to the cerebral hemisphere 
ipsilateral to the arterial occlusion. Depending on the duration of 
the hypoxia, injury may include the cerebral cortex, hippocam-
pus, striatum, and thalamus. The duration of hypoxia determines 
the extent and severity of WM damage observed in subcortical 
and PVWM. The procedure was later adapted to the preterm 
equivalent rat at P2, which corresponds to the developmental 
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stage/phenotype present in a preterm infant. At this time, highly 
vulnerable pre-oligodendrocytes are present in high numbers. In 
these circumstances, damage occurs throughout cerebral gray 
and WM (116) and is associated with behavioral deficits (41).
Hypoperfusion models in adult animals involving bilateral 
CCA stenosis have been introduced by Hattori and co-workers 
(37) and by Shibata and colleagues (35). Microcoils are wrapped 
around both CCA below the carotid bifurcation in mice to reduce 
the lumen diameter. This method results in a chronic reduction of 
CBF in the brain and induction of WM injury after 14 days without 
any gray matter involvement. In this model, the most severe WM 
injury occurs in the medial portion of the CC adjacent to the lateral 
ventricle and in the PVWM; moderate lesions are found in fiber 
bundles of the caudate-putamen and internal capsule and less 
severe lesions develop in the anterior commissure and the optic 
tracts (35). Interestingly, Yatomi et al. (117) reported that ligation 
of both CCA in rats decreased CBF by up to 60% with gradual 
improvement in flow over time. However, CBF never returned 
to baseline despite a survival time of 28 days. Following chronic 
cerebral hypoperfusion, blood–brain barrier disruption, especially 
in the CC, along with glial activation, may contribute to the patho-
genesis of WM injury (118). A recent asymmetrical hypoperfusion 
model by Ihara and colleagues reports the use of a microcoil on 
one CCA while an ameroid constrictor was applied on the other 
CCA. Ameroid constrictor absorbs water and swells, resulting in 
the constriction of the CCA while use of a microcoil acts as vascular 
stenosis. The use of these two different approaches in the same 
mouse led to a gradual decrease in CBF and by day 28, these mice 
developed functional deficits and WM degeneration (40).
Non-ischemic Stroke-Related Global  
wM injury
Hypomyelination induced by  
Lipopolysaccharide in the Developing Brain
The pathogenesis of periventricular leukomalacia appears to 
be multifactorial. Two important factors are hypoxic/ischemic 
injury and maternal-fetal infection. It has been hypothesized that 
maternal infection during the preterm period can lead to fetal 
brain injury. Clinical, epidemiological, and neuropathological 
data support maternal-fetal infection as an important pathogenic 
factor in infants with periventricular leukomalacia. Maternal 
infection increases proinflammatory cytokines levels in amniotic 
fluid and fetal blood and is associated with WM disorders such 
as periventricular leukomalacia (113, 119). Animal models of 
periventricular leukomalacia-like WM injury can be mimicked 
by injecting lipopolysaccharide (LPS) into the intraperitoneal 
cavity of pregnant rodents (120, 121) or by intravenous injection 
in ovine fetuses (45, 46). LPS has been reported to cross the 
placental barrier and induce systemic inflammation (45, 122). 
Maternal injection of LPS at gestational day 18 or 19 (G18 or G19) 
increases proinflammatory cytokines such as TNFα, IL-1α, and 
IL-6 and leads to generation of reactive oxygen species by induc-
ing depletion of peroxisomes in premyelinating oligodendrocytes 
in the fetal brain (113, 120, 123). Apoptosis has also been reported 
to be a contributing mechanism of cell death in infants with WM 
injury (124). Both in vitro and in vivo studies have shown that LPS 
causes significant toxicity to premyelinating oligodendrocytes, 
suggesting that these cells are more vulnerable to proinflamma-
tory cytokines and/or oxidative stress than mature cells (125, 
126). Furthermore, astrogliosis and microglial activation are 
hallmarks of neuroinflammation and are associated with the 
apoptosis of premyelinating oligodendrocytes that occurs in the 
wake of maternal LPS exposure (44).
Functional Deficits in the wM injury Model
Preclinical research on stroke has predominantly focused on 
models that replicate the vascular events experienced by humans. 
However, because of the enormous anatomic differences between 
rodent and human brains, the neuropathological consequences 
of induced vascular events in rodents are substantially different 
from those in patients. Thus, traditional rodent models may not 
be optimal for the study of prognosis or neurorehabilitative inter-
vention. More targeted approaches are needed. Because paresis 
in human stroke is substantially attributable to WM ischemic 
injury, the development of ischemic stroke models in rodents 
that predominantly involve WM is essential if we are to make 
progress in rehabilitation of paresis after stroke. If, on the other 
hand, the rehabilitation focus in patients is behavioral deficits 
wrought of gray matter injury (e.g., aphasia, apraxia, impairment 
in visuospatial function, hemispatial neglect, and deficits in emo-
tional function), then the traditional middle cerebral occlusion 
model in rodents, which produces predominantly gray matter 
injury, may be optimal. Furthermore, because of the degree of 
“cerebralization” of function in the human brain, it is simply not 
possible to recapitulate the functional consequences of human 
hemispheric stroke in a rodent model. For example, most patients 
with middle cerebral artery stroke permanently lose all or nearly 
all upper extremity function. Rodents with the analogous vascular 
lesion demonstrate modest and transient impairment. The central 
experimental challenge in rodent models is to develop functional 
measures sufficiently sensitive to reveal differences between treat-
ment and control groups weeks or months following the injury.
To study rehabilitation therapies, suitable animal models of 
WM injury to produce functional deficits in defined brain circuits 
and functional improvement following therapeutic interven-
tion are needed. For example, in human stroke, the type and 
extent of behavioral deficits are dependent on different parts of 
the somatosensory cortex related to the lesion locus. In global 
WM injury, in which most of the injury will encompass many 
functional circuits in the brain, morphological changes as well 
as functional deficits will become evident (Table  1). However, 
in focal WM injury models, results are inconsistent and depend 
on the techniques, drugs/chemicals used, and the location of 
lesions. The application of ET-1-induced middle cerebral artery 
occlusion is a standard ischemic model that also induces WM 
damage. This method is relatively less invasive, and important 
parameters related to reperfusion can be easily tested (127, 128). 
Similarly, occlusion of the anterior choroidal arteries (without 
compromising the anterior or middle cerebral artery origins) 
exclusively produced infarction in the striatum, including the 
internal capsule in rats (27) and pigs (28). Acute damage to the 
FiGURe 2 | Simplified schematic of white matter injury pathogenesis. 
The hypoxic-ischemic injury and vasoconstricting agents decrease cerebral 
blood flow, resulting in energy depletion and blood–brain barrier disruption in 
the WM. Demyelinating and inflammatory agents directly affect WM by 
increasing proinflammatory cytokines, gliosis, reactive oxygen species, and/
or excitatory amino acids, leading to oligodendrocyte precursor and axonal 
damage.
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PLIC can be a useful predictor of motor outcomes and prognosis 
for stroke patients (8). ET-1 has been successfully used to induce 
PLIC damage and produce a functional deficit (24, 25). However, 
injury in the CC or PVWM in animal models does not result 
in behavioral deficits (29–31), in contrast to patients with para-
ventricular leukomalcia, who do exhibit significant behavioral 
deficits. One of the important reasons for this discrepancy could 
be the substantial differences in the composition of the gray and 
WM in humans and rodents. The PLIC injuries identified in 
current studies are more likely to demonstrate functional deficits 
than the PVWM injuries; therefore, PLIC injuries represent a 
viable model for measuring motor deficits.
Mechanisms of wM injury
Innovative histological techniques have provided the foundation 
for current cellular and molecular studies on the role of proin-
flammatory cytokines, gliosis, reactive oxygen species, glutamate 
toxicity-induced oligodendroglial cell death, and demyelination 
in WM. Since the early 1970s, Leviton and Gilles have system-
atically studied PVWM injury and subsequent neurological 
disability (e.g., cerebral palsy and cognitive deficits) in premature 
infants (5, 129–132). The spectrum of chronic PVWM injury 
includes focal cystic necrotic lesions and diffuse demyelination. 
The demyelination process will then provoke the proliferation 
and migration of microglia into the lesion, and astrocytes around 
the lesion (133, 134).
The pathways (intrinsic and extrinsic) that regulate the response 
of the oligodendrocyte lineage during initial and ensuing phases 
of injury (including myelination failure) remain unclear. Further 
neuropathological studies are needed to provide guidance for 
developing animal models of WM injury. There is no definitive 
explanation of the mechanism of the WM damage caused by 
injury to oligodendrocytes produced by such acute neural insults, 
but based on some preliminary studies, it is believed that at least 
four major factors can contribute: (1) hypoxic/ischemic injury, 
(2) vasoconstriction (that may be induced by agents such as 
ET1, NOS inhibitors, etc.), (3) direct demyelination (that may be 
induced by agents such as LPC, EB, etc.), and (4) inflammatory 
processes (maternal-fetal infection induced by agents such as 
LPS) (Figure 2).
Hypoxic/ischemic conditions and vasoconstrictor agents 
reduce CBF to the target area of the brain and induce WM 
injury. WM of the mammalian central nervous system suffers 
irreversible injury when subjected to anoxia/ischemia (19, 
135, 136). Furthermore, WM in older adult mammals is more 
susceptible to ischemic injury than that in younger adults (137). 
Ischemia reduces adenosine triphosphate (ATP) and precipitates 
glutamate release due to reverse Na-dependent transport (136, 
138), resulting in the overactivation of AMPA/Kainate receptors. 
This excitotoxic condition then causes the accumulation of Ca2+ 
in cytoplasm and triggers oligodendrocyte death and axonal 
disruption (7, 135, 136, 139, 140).
The role of inflammation and excitotoxicity following WM 
injury has been suggested in numerous reports. Evidence suggests 
that several proinflammatory cytokines, including IFNγ, TNFα, 
IL-1β, IL-2, and IL-6, are elevated in periventricular leukomalacia 
(113, 141–143) and may play pivotal roles in perinatal WM injury 
(49, 144, 145). Microglial activation and astrogliosis have also 
been reported in prenatal periventricular leukomalacia (71, 146, 
147) and in an animal model of this disorder (114). Moreover, 
it has also been shown that glial cells express glutamate recep-
tors and are thus susceptible to excitotoxicity following hypoxic/
ischemic insult or treatment with a demyelinating agent (140, 
148, 149).
There is ample evidence suggesting that oxidative stress cor-
relates with the inflammatory response to ischemia-induced 
WM injury. Cerebral WM is susceptible to oxidative stress that 
particularly targets the immature stages of oligodendrocyte 
development. In addition, following hypoxic/ischemic injury, 
oxygen-free radicals contribute to chronic cerebral hypoperfu-
sion-induced WM injuries via direct cytotoxic damage involving 
lipid peroxidation and by induction of inflammatory processes 
(14, 16, 140, 149–151).
various Techniques employed to 
investigate wM injury Outcomes in  
wM Preclinical Models
Because preclinical and clinical investigations have pointed 
toward the significant role of WM in various physiologic and 
pathophysiologic conditions, these studies have primarily utilized 
novel imaging and neuropathologic tools to better understand 
the mechanisms of WM injury. In the following sub-sections, 
some of these studies have been summarized to familiarize the 
reader with these techniques; however, for greater in-depth 
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understanding of these techniques, please refer to some of these 
articles (12, 14, 151–154).
imaging
Imaging techniques have improved substantially and have paved 
the way for the analysis of WM functions. Diffusion tensor 
imaging (DTI) has been used to determine WM degeneration 
in a mouse model of hypoperfusion (155). Similarly, in a model 
of neonatal hypoxic/ischemic brain injury, WM microstructure 
integrity was assessed by MRI (156). Traumatic brain injury also 
leads to microstructural disruption in WM and these changes can 
be assessed by DTI (157, 158). Delayed WM injury can lead to 
significant functional deficit; therefore, early detection of such 
impairments is highly recommended. In a model of hypoxic/
ischemic brain damage, delayed WM injury is detected by longi-
tudinal diffusion tensor and manganese-enhanced MRI (154). In 
a mouse model of WM injury, ET-1 was injected in the subcortical 
WM and the axonal damage was studied by performing MRI (21). 
The use of such imaging techniques has improved the diagnostics 
of WM injury and provided the greater details of structural 
changes post-ischemic and other neurologic conditions.
Neuropathology
In preclinical models, several neuropathologic techniques have 
been used to test various parameters to determine WM injury. In a 
model of TBI, axonal disruption in WM was assessed by transmis-
sion electron microscopy (TEM) or immunostaining with various 
specific markers (e.g., NF200), or by performing Luxul Fast Blue 
staining (158). In a recently described model of hypoperfusion 
leading to WM injury and dementia, the severity of the WM 
lesions was determined by performing immunohistochemistry 
for the markers of astrocytes (anti-GFAP antibody), microglia 
(anti-Iba1 antibody), oligodendrocyte (anti-GST-π antibody), 
and damaged axons (anti-neurofilament H non-phosphorylated 
(SMI32) antibody) (40). The damage in WM resulted from 
hypoperfusion leading to vascular cognitive impairment and was 
quantified by performing staining for myelin basic protein (anti-
MBP) (159). Several other immunohistochemical markers have 
been targeted to understand some of the mechanisms associated 
with WM injury (160–163). These well-established immunohis-
tochemical protocols provide greater detail into the role of WM 
in acute neurologic conditions and help in better understanding 
the mechanisms associated with WM injuries.
Optimization of induced wM injury
As discussed above, several models of WM injury induced 
by vasoconstricting agents, demyelinating agents, or vascular 
manipulations have been reported. The extent of injury is depend-
ent on many factors, including the drugs or agents administered, 
brain areas targeted, gender, age, and survival time point post-
injection. Consequently, most of these studies report anatomical 
outcomes and only a few studies correlate anatomical outcomes 
with functional changes (Table 1). Use of agents such as ET-1, 
LPC, or L-NIO, in addition to other compounds/strategies and 
their related injection sites, provide a plethora of information that 
has improved our understanding toward the pathophysiology of 
WM injury during stroke. However, WM injury models that can 
be truly referred as a WM injury model of ischemic stroke need 
further refining. Therefore, some considerations, as discussed 
below, should be taken into account for optimizing an induced 
WM injury model relevant with stroke.
First, it is important to choose a brain region that is mostly 
affected during ischemic stroke. One such area is PLIC or IC. This 
brain region is an important area to control motor functions and 
is substantially affected soon after the onset of stroke (164–167). 
Therefore, targeting this WM brain area will most likely provide a 
better and consistent WM injury model. The second aspect to con-
sider is to have a better choice of WM injury-inducing chemicals 
(such as ET-1, L-NIO, or LPC). The advantage with ET-1 and L-NIO, 
in terms of stroke research, is that these vasoconstricting agents 
result in irreversible focal infarction, whereas the demyelinating 
agent LPC induces diffused reversible WM injury. A limitation 
of ET-1 is that it also has receptor-mediated effects on OPC and 
astrocytes. Therefore, use of ET-1 as an agent to induce ischemic 
stroke in WM may confound the interpretation of neural repair 
tissue outcomes because these outcomes could be due to the direct 
ischemic effect of ET-1, or due to the effect of ET-1 on astrocytes 
and OPCs. Third, the dose of these agents at one single location or 
multiple locations of the same WM region should also be consid-
ered for a sustained WM injury model. Because the effectiveness 
of ET-1 in mice is still questionable, a combination of ET-1 and 
L-NIO can also be considered as an option for the stroke-related 
WM injury model. These are some of the basic considerations to 
optimize chemical-induced WM injury models. Some considera-
tions for other WM injury models that are beyond the scope of this 
review can be found in these articles (11–16, 19, 20).
Conclusion
Given the advances in various animal models of WM injury 
developed to understand the mechanisms of disease, a focus on 
disease management continues to increase. The crucial need to 
understand the cellular and molecular events that accompany the 
progressive phases of WM injury and demyelination in patients 
has led to the use of animal models. However, there has only been 
moderate success in translation using the proposed WM injury 
models, especially for mimicking functional deficits that occur 
in patients. Although current animal models do not reproduce 
all the clinical features of WM disease, they provide valuable 
information regarding disease mechanisms and disease-related 
neurobiological pathways, and they assist in testing possible 
interventions. The fact that the human brain differs considerably 
from rodents must be appreciated: such differences account for 
variations in lesion volumes and behavioral outcomes. In finding 
novel therapies for WM injuries, the first and foremost require-
ment is an in-depth knowledge of the neuropathology associated 
with the disorder while taking into account the complexity of WM 
and its distribution in the brain. Such an effort on development of 
optimized WM preclinical models holds great promise in leading 
to a comprehensive understanding of the disease mechanisms 
and in finding novel therapies that can alleviate the suffering of 
a significant portion of the population that is encountering this 
devastating disease.
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